Lepu Biopharma Co (HKSE:02157) Shares Outstanding (EOP): 1,804 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02157 Lepu Biopharma Co Ltd HKSE:02157
44 GF Score
Price HK$4.65
GF Value HK$15.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Lepu Biopharma Co Shares Outstanding (EOP)?

Lepu Biopharma Co HKSE:02157 -2.92% 44 Shares Outstanding (EOP) is 1,804 Mil as of Dec. 2025. GuruFocus rates HKSE:02157 with a GF Score™ of 44/100 and a GF Value™ of HK$15.69 (Possible Value Trap). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Lepu Biopharma Co's shares outstanding for the quarter that ended in Dec. 2025 was 1,804 Mil.

Lepu Biopharma Co's quarterly shares outstanding increased from Jun. 2025 (1,711 Mil) to Dec. 2025 (1,804 Mil). It means Lepu Biopharma Co issued new shares from Jun. 2025 to Dec. 2025 .

Lepu Biopharma Co's annual shares outstanding increased from Dec. 2024 (1,711 Mil) to Dec. 2025 (1,804 Mil). It means Lepu Biopharma Co issued new shares from Dec. 2024 to Dec. 2025 .


Lepu Biopharma Co  (HKSE:02157) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Lepu Biopharma Co Shares Outstanding (EOP) Related Terms


Lepu Biopharma Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Lepu Biopharma Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lepu Biopharma Co Shares Outstanding (EOP) Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 1,658.55 1,659.45 1,659.45 1,710.62 1,804.44

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,659.45 1,710.62 1,710.62 1,710.62 1,804.44

HKSE:02157 vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Lepu Biopharma Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lepu Biopharma Co Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Lepu Biopharma Co's Shares Outstanding (EOP) falls into.


HKSE:02157
44GF Score
Lepu Biopharma Co Ltd HKSE:02157
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lepu Biopharma Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 1,804 Mil mean?
Lepu Biopharma Co (HKSE:02157) has a Shares Outstanding (EOP) of 1,804 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Lepu Biopharma Co and its competitors.
Is Lepu Biopharma Co's Shares Outstanding (EOP) too high?
Lepu Biopharma Co's current Shares Outstanding (EOP) is 1,804 Mil. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Shares Outstanding (EOP) compare to VRTX and REGN?
Lepu Biopharma Co's Shares Outstanding (EOP) of 1,804 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Shares Outstanding (EOP) is 1,804 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.69, compared to a current price of HK$4.65 — trading 70.4% below its estimated fair value. The current Shares Outstanding (EOP) is 1,804 Mil. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Shares Outstanding (EOP) is 1,804 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?

Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued. The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69. GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.

Key valuation signals for HKSE:02157:

  • Shares Outstanding (EOP): 1,804 Mil
  • GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lepu Biopharma Co Business Description

Address Lianheng Road, Block 4, No. 651, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for HKSE:02157

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.65
Price
HK$15.69
GF Value